XNCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. XNCR is sitting just above near-term support (~12.03) but the trend/momentum is still bearish (MACD histogram negative and expanding) and there are no near-term news catalysts. Options positioning is modestly bullish (put/call OI < 1), yet insiders have been heavy sellers recently, which is a near-term negative. For an impatient buyer looking for immediate upside, the setup is unfavorable unless you are specifically taking a quick oversold bounce trade off support.
Price action is weak: the stock closed at 12.09 (-2.34%) and is trading below the pivot (12.766), implying bearish control. Momentum is deteriorating with a MACD histogram at -0.0709 and negatively expanding (downtrend strengthening). RSI(6) is ~26, which indicates an oversold/washed-out condition and increases the odds of a short-term bounce, but oversold alone is not a reversal signal. Key levels: immediate support S1=12.031 (price is hovering right on it); if that breaks, next support S2=11.576. Overhead resistance starts at the pivot 12.766, then R1=13.501. With converging moving averages, the stock may be basing, but it has not reclaimed key resistance. Pattern-based projection provided: ~70% chance of -1.17% next day, +2.95% next week, -0.23% next month—suggesting choppy, not a clean upside trend.
~26, near S1=12.
can produce a short, tradable bounce.
No news/catalysts in the last week to trigger an immediate re-rating, making a quick upside move less likely for an impatient buyer. Bearish momentum: MACD negative and worsening; price below pivot. Insider activity is a clear negative: insiders are selling and the selling amount increased ~2127% over the last month. Financials show worsening profitability (Q3 loss expanded sharply), which can weigh on sentiment without near-term clinical/partner catalysts.
Latest reported quarter: 2025/Q3. Revenue rose to ~$21.0M (+18% YoY), indicating some top-line growth. However, profitability deteriorated materially: net income fell to about -$6.0M (down ~87% YoY) and EPS declined to -$0.08 (down ~89% YoY). Gross margin shown as 100% (likely accounting for revenue mix typical of biotech collaborations), but the key takeaway is: revenue is improving while losses are widening—consistent with ongoing R&D spend and not yet a clear inflection toward earnings leverage.
Recent trend: price targets have generally moved up and coverage has been constructive. Barclays (Overweight) raised PT to $26 (from $23). BofA stayed Neutral but raised PT to $20 (from $17), signaling improved sector/stock outlook but not enough to turn bullish. Truist initiated Buy with a $29 PT, highlighting TL1A and broader pipeline. JPMorgan (Overweight) trimmed PT to $18 (from $20) after Q3, a modest near-term reset. Cantor remained very bullish (Overweight) and raised PT to $42 (from $40), emphasizing expected clinical progress over the next year. Wall Street pros: pipeline/clinical optionality (TL1A, T-cell engagers), improving biotech sentiment, potential M&A/in-licensing backdrop. Cons: near-term execution risk typical of biotech, recent financial loss expansion, and the stock is currently trading with weak technical momentum despite bullish long-term targets.
